has been cited by the following article(s):
|
[1]
|
Lifetime economic burden of hemophilia using a nationwide real-world healthcare data
PLOS One,
2025
DOI:10.1371/journal.pone.0333683
|
|
|
|
|
[2]
|
Evolution of congenital haemophilia care in Taiwan
Journal of the Formosan Medical Association,
2022
DOI:10.1016/j.jfma.2021.07.017
|
|
|
|
|
[3]
|
Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study
BMC Health Services Research,
2022
DOI:10.1186/s12913-022-07626-x
|
|
|
|
|
[4]
|
Trends in coagulation factor replacement therapy and medical costs in patients with haemophilia in Taiwan: A population‐based, 15‐year analysis
Haemophilia,
2021
DOI:10.1111/hae.14250
|
|
|
|
|
[5]
|
Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia
Journal of Korean Medical Science,
2016
DOI:10.3346/jkms.2016.31.1.33
|
|
|
|
|
[6]
|
The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study
PLOS ONE,
2016
DOI:10.1371/journal.pone.0164009
|
|
|
|